Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Mallinckrodt
Teva
Healthtrust
Harvard Business School
Fuji
Moodys
US Department of Justice
Dow

Generated: November 15, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207350

« Back to Dashboard

NDA 207350 describes MAGNESIUM SULFATE IN PLASTIC CONTAINER, which is a drug marketed by Fresenius Kabi Usa, Hospira, Hq Spclt Pharma, and Mylan Labs Ltd, and is included in four NDAs. It is available from five suppliers. Additional details are available on the MAGNESIUM SULFATE IN PLASTIC CONTAINER profile page.

The generic ingredient in MAGNESIUM SULFATE IN PLASTIC CONTAINER is magnesium sulfate. There are one hundred and forty drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the magnesium sulfate profile page.
Summary for 207350
Tradename:MAGNESIUM SULFATE IN PLASTIC CONTAINER
Applicant:Hq Spclt Pharma
Ingredient:magnesium sulfate
Patents:0
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 207350
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MAGNESIUM SULFATE IN PLASTIC CONTAINER magnesium sulfate INJECTABLE;INJECTION 207350 ANDA WG Critical Care, LLC 44567-420 44567-420-24 24 POUCH in 1 CARTON (44567-420-24) > 1 BAG in 1 POUCH (44567-420-00) > 50 mL in 1 BAG
MAGNESIUM SULFATE IN PLASTIC CONTAINER magnesium sulfate INJECTABLE;INJECTION 207350 ANDA WG Critical Care, LLC 44567-421 44567-421-24 24 POUCH in 1 CARTON (44567-421-24) > 1 BAG in 1 POUCH (44567-421-00) > 100 mL in 1 BAG

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength2GM/50ML (40MG/ML)
Approval Date:Dec 6, 2017TE:APRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength4GM/100ML (40MG/ML)
Approval Date:Dec 6, 2017TE:APRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength4GM/50ML (80MG/ML)
Approval Date:Dec 6, 2017TE:APRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Chinese Patent Office
Healthtrust
Argus Health
McKinsey
US Department of Justice
Boehringer Ingelheim
Teva
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.